Myeloma

After a median follow-up of 13.3 months, the median overall response rate across all patients who received idecabtagene vicleucel (ide-cel) was 73%, including a complete response of 33%.

CC-92480, a novel cereblon E3 ligase modulator agent, in combination with dexamethasone appeared safe and active in patients with heavily pretreated relapsed or refractory multiple myeloma, according to data presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

The addition of the novel drug Xpovio to the regimen of Velcade and dexamethasone delayed disease progression, reduced peripheral neuropathy and required fewer office visits in a study of previously treated patients with multiple myeloma.

New findings, presented at the 2020 ASCO Virtual Scientific Program, suggest that the standard of care for newly diagnosed patients with multiple myeloma remains as Kyprolis triplet does not improve outcomes.

Understanding multiple myeloma.

In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 & Cancer Care for Patients”, Dr. Farukh Awan addresses how the new coronavirus has impacted patient care for those diagnosed with chronic lymphocytic leukemia and myeloma.

The Food and Drug Administration approved Darzalex Faspro (daratumumab and hyaluronidase-fihj), a subcutaneous form of Darzalex, for adults with newly diagnosed or relapsed/refractory multiple myeloma.

Here is a list of the recent trial initiations that occurred within the cancer space in April.

“Only you have the power to make your life better,” says a myeloma survivor on living for the moment after a cancer diagnosis.

A new genetic test that identifies patients with multiple myeloma who have high-risk genetics may help oncologists find alternative treatment options before the disease progresses.

“I just want people to know that when they say you have cancer, they are not saying you have a death sentence. You can still live and you can live well.”

Patients with relapsed and refractory multiple myeloma (RRMM) who had previously received multiple lines of therapy experienced a durable clinical benefit after receiving melflufen (Oncopeptides) in combination with dexamethasone.

The Food and Drug Administration approved the targeted therapy Sarclisa for the treatment of patients with multiple myeloma. Here’s what you need to know.

Terry White, who has lived with multiple myeloma for more than a decade, offers reassurance to other patients.

In this episode of the “CURE Talks Cancer” podcast, we spoke with the co-chair of the MMRF’s Laugh for Life event, as well as this year’s “Spirit of Hope” award recipient.

The Food and Drug Administration approved Sarclisa, as adding the targeted drug to combination therapy delays the progression of multiple myeloma in previously treated patients.

Patient Rod Gilmore shares his experience with multiple myeloma and the importance of creating a strategy to manage the disease.

The Food and Drug Administration granted a priority review to belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma.